Back to Search
CHRISTIE BALLANTYNE, MD
MD
Cardiovascular Disease Physician
NPI: 1467471557IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
G3128(TX)
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
G3128(TX)
Education
BAYLOR COLLEGE OF MEDICINE
Class of 1982
Clinical Trials (2)
2
Linked Trials
0
Recruiting
2
With Results
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.
NCT00988364COMPLETEDPHASE4STUDY_DIRECTOR
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
NCT00687076COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Research & Publications (20)
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).
PMID 24267254·Atherosclerosis·2013
4-observational
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients.
PMID 21227624·J Vasc Surg·2011
4-observational
Pro-apoptotic low-density lipoprotein subfractions in type II diabetes.
PMID 17030034·Atherosclerosis·2007
7-preclinical
Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management.
PMID 17345122·World J Surg·2007
6-review
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
PMID 14757686·Circulation·2004
8-other
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
PMID 15383192·Curr Med Res Opin·2004
3-trial
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
PMID 12719279·Circulation·2003
3-trial
LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
PMID 12637336·Arterioscler Thromb Vasc Biol·2003
8-other
Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins.
PMID 12689919·Arterioscler Thromb Vasc Biol·2003
7-preclinical
Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription.
PMID 12695302·Circulation·2003
7-preclinical
Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity.
PMID 11805008·Clin Chem·2002
8-other
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
PMID 11375333·Diabetes·2001
7-preclinical
Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells.
PMID 11031216·Arterioscler Thromb Vasc Biol·2000
4-observational
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
PMID 18702965·J Am Coll Cardiol·2008
4-observational
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden.
PMID 18378607·Circulation·2008
3-trial
Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study.
PMID 18469836·Int J Obes (Lond)·2008
4-observational
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
PMID 18471454·Am J Cardiol·2008
3-trial
Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors.
PMID 17948362·Clin Cornerstone·2007
6-review
Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?
PMID 17667863·Crit Pathw Cardiol·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 6565 FANNIN, B160
HOUSTON, TX 77030 - Phone
- (713) 798-5034
Quick Facts
- NPI
- 1467471557
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 44
- Clinical Trials
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile